Evolution of the role of haploidentical stem cell transplantation: past, present, and future

References

• Thomas D, Storb R, Clift R. Bone-marrow transplantation (first of two parts). N Engl J Med. 1975;292:832–843.
   PubMed Web of Science ®Google Scholar
• Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729–735.
   PubMed Web of Science ®Google Scholar
• Hansen J, Clift R, Thomas E, et al. Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med. 1980;303:565–567.
   PubMed Web of Science ®Google Scholar
• Powles R, Morgenstern H, Kay E, et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukemia. Lancet. 1983;1:612–615.
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-Cell–Depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186–1193.
   PubMed Web of Science ®Google Scholar
• WMDA. World Marrow Donor Association (WMDA) Annual Report. 2018.
   Google Scholar
• Rosenmayr A, Pointner-Prager M, Mitterschiffthaler A, et al. What are a patient’s current chances of finding a matched unrelated donor? Twenty years’ central search experience in a small country. Bone Marrow Transplant. 2012;47:172–180.
   PubMed Web of Science ®Google Scholar
• Pidala J, Kim J, Schell M, et al. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2013;48:346–350.
   PubMed Web of Science ®Google Scholar
• Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321:1174–1178.
   PubMed Web of Science ®Google Scholar
• Wagner JE, Eapen M, Carter S, et al. One-Unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med. 2014;371:1685–1694.
   PubMed Web of Science ®Google Scholar
• Kwon M, Bautista G, Balsalobre P, et al. Haplo-cord transplantation using CD34+ cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders. Biol Blood Marrow Transplant. 2014;20:2015–2022.
   PubMed Web of Science ®Google Scholar
• Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet. 1981;2:327–331.
   PubMed Web of Science ®Google Scholar
• Beatty PG, Clift R, Mickelson E. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313:765–771.
   PubMed Web of Science ®Google Scholar
• Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990;29:79–91.
   PubMed Web of Science ®Google Scholar
• Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. JCO. 1997;15:1767–1777.
   PubMed Web of Science ®Google Scholar
• Chen X-H, Gao L, Zhang X, et al. HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation. Blood Cells Mol Dis. 2009;43:98–104.
   PubMed Web of Science ®Google Scholar
• Bashey A, Zhang X, Sizemore CA, et al. T-Cell–replete HLA-Haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-Matched related and unrelated donor transplantation. JCO. 2013;31:1310–1316.
   PubMed Web of Science ®Google Scholar
• Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13:10–24. .
   PubMed Web of Science ®Google Scholar
• Martelli M, Reisner Y. Haploidentical ‘megadose’ CD34+ cell transplants for patients with acute leukemia. Leukemia. 2002;16:404–405.
   PubMed Web of Science ®Google Scholar
• Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase ii study in patients with acute leukemia at high risk of relapse. JCO. 2005;23:3447–3454. .
   PubMed Web of Science ®Google Scholar
• Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112:3574–3581.
   PubMed Web of Science ®Google Scholar
• Handgretinger R. Negative depletion of CD3+ and TcRαβ+ T cells: current opinion in hematology. Curr Opin Hematol. 2012;19:434–439.
   Google Scholar
• Saad A, Lamb LS. Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future. Bone Marrow Transplant. 2017;52:1241–1248.
   PubMedGoogle Scholar
• Jun HX, Jun CY, Yu ZX. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. 8. 2004.
   Google Scholar
• Huang X-J, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol. 2007;17:193–197.
   PubMed Web of Science ®Google Scholar
• Pan L, Delmonte JJ, Jalonen C, et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 1995;86:4422–4429.
   PubMed Web of Science ®Google Scholar
• Zeng D, Dejbakhsh-Jones S, Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood. 1997;90:453–463.
   PubMed Web of Science ®Google Scholar
• Huang X-J, Liu D-H, Liu K-Y, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38:291–297.
   PubMed Web of Science ®Google Scholar
• Lu D-P, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065–3073. .
   PubMed Web of Science ®Google Scholar
• Wang Y, Chang Y-J, Xu L-P, et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014;124:843–850.
   PubMed Web of Science ®Google Scholar
• Yan C-H, Liu D-H, Liu K-Y, et al. Risk stratification–directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119:3256–3262.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang Y, Hu B, et al. Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord–derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-Haploidentical stem-cell transplantation. JCO. 2016;34:2843–2850.
   PubMed Web of Science ®Google Scholar
• Martin PJ, Pei J, Gooley T, et al. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant. 2004;10:552–560.
   PubMed Web of Science ®Google Scholar
• Arcese W, Santarone S, De Angelis G, et al. Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update. Bone Marrow Transplant. 2015;50:S24–S30.
   PubMedGoogle Scholar
• Santos G, Owens A. Production of Graft-Versus-Host Disease in the Rat and Its Treatment With Cytotoxic Agents. Nature. 1966;210:139–140.
   PubMed Web of Science ®Google Scholar
• Santos G, Brookmeyer R, Saral R, et al. Cyclosporine (CsA) versus Cyclophosphamide (CY): prevention of graft-versus-host disease (GVHD). Exp Hematol. 1985;13:427.
   Web of Science ®Google Scholar
• Luznik L, Jalla S, Engstrom L, et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456–3464.
   PubMed Web of Science ®Google Scholar
• Kanakry CG, Ganguly S, Zahurak M, et al. Aldehyde dehydrogenase expression drives human regulatory T Cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5:211ra157–211ra157.
   PubMed Web of Science ®Google Scholar
• Ross D, Jones M, Komanduri K, et al. Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1430–1438.
   PubMed Web of Science ®Google Scholar
• O’Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377–386.
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell PV, Symons HJ, et al. HLA-Haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–650. .
   PubMed Web of Science ®Google Scholar
• Nunes NS, Kanakry CG. Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding. Front Immunol. 2019;10:2668.
   PubMed Web of Science ®Google Scholar
• Solomon SR, Sizemore CA, Sanacore M, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective Phase II trial. Biol Blood Marrow Transplant. 2012;18:1859–1866.
   PubMed Web of Science ®Google Scholar
• Solomon SR, Sizemore CA, Sanacore M, et al. Total body irradiation–based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant. 2015;21:1299–1307.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignancies following a myeloablative conditioning: an update. Bone Marrow Transplant. 2015;50:S37–S39.
   PubMed Web of Science ®Google Scholar
• Esquirol A, Pascual MJ, Ortiz M, et al. Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies. Bone Marrow Transplant. 2017;52:1273–1279.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Kanakry JA, Ahn KW, et al. Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide–based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2019;25:1859–1868.
   PubMed Web of Science ®Google Scholar
• Martínez C, Gayoso J, Canals C, et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the lymphoma working party of the european society for blood and marrow transplantation. JCO. 2017;35:3425–3432.
   PubMed Web of Science ®Google Scholar
• Salvatore D, Labopin M, Ruggeri A, et al. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2018;103:1317–1328.
   PubMed Web of Science ®Google Scholar
• Devillier R, Legrand F, Rey J, et al. HLA-Matched sibling versus unrelated versus haploidentical related donor allogeneic hematopoietic stem cell transplantation for patients aged over 60 years with acute myeloid leukemia: a single-center donor comparison. Biol Blood Marrow Transplant. 2018;24:1449–1454.
   PubMedGoogle Scholar
• Dreger P, Sureda A, Ahn KW, et al. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019;3:360–369.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Zhang M-J, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033–1040.
   PubMed Web of Science ®Google Scholar
• Perales M-A, Tomlinson B, Zhang M-J, et al. Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor? Haematologica. 2020;105:407–413.
   PubMed Web of Science ®Google Scholar
• Gagelmann N, Bacigalupo A, Rambaldi A, et al. Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A Systematic Review and Meta-analysis. JAMA Oncol. 2019;5:1379–1748.
   Web of Science ®Google Scholar
• Wang Y, Liu Q-F, Xu L-P, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125:3956–3962.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Q-F, Xu L-P, et al. Haploidentical versus matched-sibling transplant in adults with philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase iii randomized study. Clin Cancer Res. 2016;22:3467–3476.
   PubMed Web of Science ®Google Scholar
• Sanz J, Montoro J, Solano C, et al. Prospective randomized study comparing myeloablative unrelated umbilical cord blood transplantation versus HLA-Haploidentical related stem cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2020;26:358–366.
   PubMed Web of Science ®Google Scholar
• Giannotti F, Labopin M, Shouval R, et al. Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. J Hematol Oncol. 2018;11:110.
   PubMed Web of Science ®Google Scholar
• Fatobene G, Rocha V, St. Martin A, et al. Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma: from the LWP-EBMT, Eurocord, and CIBMTR. JCO. 2020;38:1518–1526.
   PubMed Web of Science ®Google Scholar
• Esquirol A, Querol S, Garcia-Cadenas I, et al. When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (thiotepa-busulfan-fludarabine). Ann Hematol. 2020;99:157–165.
   PubMed Web of Science ®Google Scholar
• Kwon M, Bautista G, Balsalobre P, et al. Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML. Bone Marrow Transplant. 2017;52:1138–1143.
   PubMedGoogle Scholar
• van Besien K, Artz A, Champlin RE, et al. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019;3:1858–1867.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118:282–288.
   PubMed Web of Science ®Google Scholar
• Lee CJ, Savani BN, Mohty M, et al. Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:1810–1822.
   PubMed Web of Science ®Google Scholar
• Duarte RF, Bader P, Basak GW, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019;54:1525–1552.
   PubMed Web of Science ®Google Scholar
• Gayoso J, Balsalobre P, Pascual MJ, et al. Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: spanish multicenter experience. Bone Marrow Transplant. 2016;51:1307–1312.
   PubMedGoogle Scholar
• Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129:1548–1556.
   PubMed Web of Science ®Google Scholar
• Shenoy S, Eapen M, Panepinto JA, et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016;128:2561–2567.
   PubMed Web of Science ®Google Scholar
• de la Fuente J, Dhedin N, Koyama T, et al. Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: results of an International Learning Collaborative. Biol Blood Marrow Transplant. 2019;25:1197–1209.
   PubMed Web of Science ®Google Scholar
• Gaziev J, Isgro A, Sodani P, et al. Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCRab1/CD191-depleted grafts. Blood Adv. 2018;13:263–270.
   Google Scholar
• Foell J, Schulte JH, Pfirstinger B, et al. Haploidentical CD3 or α/β T-cell depleted HSCT in advanced stage sickle cell disease. Bone Marrow Transplant. 2019;54:1859–1867.
   PubMed Web of Science ®Google Scholar
• Patel DA, Akinsete AM, Connelly JA, et al. T-cell deplete versus T-cell replete haploidentical hematopoietic stem cell transplantation for sickle cell disease: where are we? Expert Rev Hematol. 2019;12:733–752.
   PubMed Web of Science ®Google Scholar
• Anurathapan U, Hongeng S, Pakakasama S, et al. Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors. Bone Marrow Transplant. 2016;51:813–818.
   PubMed Web of Science ®Google Scholar
• Oevermann L, Schulte JH, Hundsdörfer P, et al. HLA-haploidentical hematopoietic stem cell transplantation in pediatric patients with hemoglobinopathies: current practice and new approaches. Bone Marrow Transplant. 2019;54:743–748.
   PubMedGoogle Scholar
• Andreani M, Gianolini ME, Testi M, et al. Mixed chimerism evolution is associated with T regulatory type 1 (Tr1) cells in a β-thalassemic patient after haploidentical haematopoietic stem cell transplantation. Chimerism. 2014;5:75–79.
   PubMedGoogle Scholar
• Andreani M, Gregori S. The study of engraftment after hematopoietic stem cell transplantation: from the presence of mixed chimerism to the development of immunological tolerance. HLA. 2018;92:57–59.
   PubMed Web of Science ®Google Scholar
• Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172:187–207.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. Alternative donor transplants for severe aplastic anemia. Hematology. 2018;2018:467–473.
   PubMedGoogle Scholar
• DeZern AE, Zahurak M, Symons H, et al. Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2017;23:498–504.
   PubMed Web of Science ®Google Scholar
• Xu L-P, Jin S, Wang S-Q, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol. 2017;10:25.
   PubMed Web of Science ®Google Scholar
• DeZern AE, Zahurak ML, Symons HJ, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4:1770–1779.
   PubMed Web of Science ®Google Scholar
• Georges GE, Doney K, Storb R. Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment. Blood Adv. 2018;2:2020–2028.
   PubMed Web of Science ®Google Scholar
• Acevedo MJ, Wilder JS, Adams S, et al. Outcomes of related and unrelated donor searches among patients with primary immunodeficiency diseases referred for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25:1666–1673.
   PubMedGoogle Scholar
• Uppuluri R, Sivasankaran M, Patel S, et al. Haploidentical stem cell transplantation with post-transplant cyclophosphamide for primary immune deficiency disorders in children: challenges and outcome from a tertiary care center in South India. J Clin Immunol. 2019;39:182–187.
   PubMed Web of Science ®Google Scholar
• Mattsson J, Ringdén O, Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14:165–170.
   PubMed Web of Science ®Google Scholar
• Crocchiolo R, Ciceri F, Fleischhauer K, et al. HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. Bone Marrow Transplant. 2009;44:571–577.
   PubMed Web of Science ®Google Scholar
• Olsson R, Remberger M, Schaffer M, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48:537–543.
   PubMed Web of Science ®Google Scholar
• Spellman S, Bray R, Rosen-Bronson S, et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood. 2010;115:2704–2708.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Thall PF, Milton DR, et al. Complement-binding donor-specific Anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21:1392–1398.
   PubMedGoogle Scholar
• Gladstone DE, Bettinotti MP. HLA donor-specific antibodies in allogeneic hematopoietic stem cell transplantation: challenges and opportunities. Hematology. 2017;2017:645–650.
   PubMedGoogle Scholar
• Ciurea SO, Cao K, Fernandez-Vina M, et al. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2018;53:521–534.
   PubMed Web of Science ®Google Scholar
• Leffell MS, Jones RJ, Gladstone DE. Donor HLA-specific Abs: to BMT or not to BMT? Bone Marrow Transplant. 2015;50:751–758.
   PubMed Web of Science ®Google Scholar
• Kwon M, Martínez-Laperche C, Balsalobre P, et al. Early peripheral blood and T-cell chimerism dynamics after umbilical cord blood transplantation supported with haploidentical cells. Bone Marrow Transplant. 2014;49:212–218.
   PubMedGoogle Scholar
• Díez-Martín JL, Gómez-Pineda A, Serrano D, et al. Successful treatment of incipient graft rejection with donor leukocyte infusions, further proof of a graft versus host lymphohaemopoietic effect. Bone Marrow Transplant. 2004;33:1037–1041.
   PubMed Web of Science ®Google Scholar
• Schriber J, Agovi M-A, Ho V, et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant. 2010;16:1099–1106.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Lucarelli B, Merli P. Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opin Pharmacother. 2014;15:23–36.
   PubMed Web of Science ®Google Scholar
• Larocca A, Piaggio G, Podestà M, et al. A boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica. 2006;91:935–40pr.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Song J, Jiang Z, et al. Risk-Factor Analysis of Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Int J Med Sci. 2014;11:652–657.
   PubMed Web of Science ®Google Scholar
• Shi -M-M, Kong Y, Song Y, et al. Atorvastatin enhances endothelial cell function in posttransplant poor graft function. Blood. 2016;128:2988–2999.
   PubMed Web of Science ®Google Scholar
• Kong Y, Wang Y, Zhang -Y-Y, et al. Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Adv. 2019;3:1303–1317.
   PubMed Web of Science ®Google Scholar
• Sun Y-Q, He G-L, Chang Y-J, et al. The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. Ann Hematol. 2015;94:1699–1705.
   PubMed Web of Science ®Google Scholar
• Gómez-Centurión I, Kwon M. Poor graft function after unmanipulated haploidentical SCT with post-transplant high dose cyclophosphamide (abstract). Bone Marrow Transplant. 2019;54:243–244.
   Web of Science ®Google Scholar
• Tanaka T, Inamoto Y, Yamashita T, et al. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22:919–924.
   PubMed Web of Science ®Google Scholar
• Tang C, Chen F, Kong D, et al. Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag. J Hematol Oncol. 2018;11:103.
   PubMed Web of Science ®Google Scholar
• Bento L, Bastida JM, García-Cadenas I, et al. Thrombopoietin receptor agonists for severe thrombocytopenia after allogeneic stem cell transplantation: experience of the spanish group of hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2019;25:1825–1831.
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–195.
   PubMed Web of Science ®Google Scholar
• Colvin GA, Berz D, Ramanathan M, et al. Nonengraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: tumor Responses without Chimerism. Biol Blood Marrow Transplant. 2009;15:421–431.
   PubMed Web of Science ®Google Scholar
• Castagna L, Crocchiolo R, Furst S, et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2014;20:724–729.
   PubMed Web of Science ®Google Scholar
• Raj K, Pagliuca A, Bradstock K, et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014;20:890–895.
   PubMed Web of Science ®Google Scholar
• O’Donnell P, Raj K, Pagliuca A. High Fever Occurring 4 to 5 Days Post-Transplant of Haploidentical Bone Marrow or Peripheral Blood Stem Cells after Reduced-Intensity Conditioning Associated with the Use of Post-Transplant Cyclophosphamide as Prophylaxis for Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2015;21:197–198.
   PubMed Web of Science ®Google Scholar
• Chen Y, Huang X-J, Wang Y, et al. Febrile reaction associated with the infusion of haploidentical peripheral blood stem cells: incidence, clinical features, and risk factors: IRFR after the Infusion of Haploidentical PBSCs. Transfusion. 2015;55:2023–2031.
   PubMed Web of Science ®Google Scholar
• Abboud R, Keller J, Slade M, et al. Severe cytokine-release syndrome after T cell–replete peripheral blood haploidentical donor transplantation is associated with poor survival and Anti–IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transplant. 2016;22:1851–1860.
   PubMed Web of Science ®Google Scholar
• Raj RV, Hamadani M, Szabo A, et al. Peripheral blood grafts for T cell–replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome. Biol Blood Marrow Transplant. 2018;24:1664–1670.
   PubMed Web of Science ®Google Scholar
• Solán L, Landete E, Bailén R, et al. Cytokine release syndrome after allogeneic stem cell transplantation with post transplant cyclophosphamide. Blood. 2018;132:3367.
   Google Scholar
• Imus PH, Blackford AL, Bettinotti M, et al. Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:2431–2437.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–448.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.
   PubMed Web of Science ®Google Scholar
• Nishimoto M, Hirose A, Koh H, et al. Clinical impacts of using serum IL-6 level as an indicator of cytokine release syndrome after HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2019;25:2061–2069.
   PubMed Web of Science ®Google Scholar
• Cho C, Perales MA. Rapid identification of cytokine release syndrome after haploidentical PBSC transplantation and successful therapy with tocilizumab. Bone Marrow Transplant. 2016;51:1620–1621.
   PubMed Web of Science ®Google Scholar
• Spitzer T. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:893–898.
   PubMed Web of Science ®Google Scholar
• Maiolino A, Biasoli I, Lima J, et al. Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria. Bone Marrow Transplant. 2003;31:393–397.
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu L-P, Liu K-Y, et al. High incidence of engraftment syndrome after haploidentical allogeneic stem cell transplantation. Eur J Haematol. 2016;96:517–526.
   PubMed Web of Science ®Google Scholar
• Landete E, Solán L, Bailén R, et al. Engraftment syndrome after haploidentical stem cell transplantation with post-transplant cyclophosphamide (abstract). Bone Marrow Transplant. 2019;54:68–69.
   PubMedGoogle Scholar
• Mohty M, Malard F, Abecassis M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51:906–912.
   PubMed Web of Science ®Google Scholar
• Gómez-Centurión I, Dorado N, Bailén R, et al. Transjugular Intrahepatic Portosystemic Shunt (TIPS) for very severe veno-occlusive disease after unmanipulated haploidentical HSCT with post-transplant cyclophosphamide. Blood. 2019;134:1981.
   Web of Science ®Google Scholar
• Atilla E, Atilla PA, Bozdağ SC, et al. A review of infectious complications after haploidentical hematopoietic stem cell transplantations. Infection. 2017;45:403–411.
   PubMed Web of Science ®Google Scholar
• Chang Y-J, Zhao X-Y, Huang X-J. Immune Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2014;20:440–449.
   PubMed Web of Science ®Google Scholar
• Mehta RS, Rezvani K. Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. Virulence. 2016;7:901–916.
   PubMed Web of Science ®Google Scholar
• Aversa F, Pierini A, Ruggeri L, et al. The evolution of T cell depleted haploidentical transplantation. Front Immunol. 2019;10:2769.
   PubMed Web of Science ®Google Scholar
• Chang Y-J, Zhao X-Y, Huo M-R, et al. Immune reconstitution following unmanipulated HLA-Mismatched/Haploidentical transplantation compared with HLA-identical sibling transplantation. J Clin Immunol. 2012;32:268–280.
   PubMed Web of Science ®Google Scholar
• Aversa F, Prezioso L, Manfra I, et al. Immunity to infections after haploidentical hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis. 2016;8:2016057.
   Web of Science ®Google Scholar
• Crocchiolo R, Bramanti S, Vai A, et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis. 2015;17:242–249.
   PubMed Web of Science ®Google Scholar
• Slade M, Goldsmith S, Romee R, et al. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transpl Infect Dis. 2017;19:e12629.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Raiola AM, Galaverna F, et al. Pre-engraftment bloodstream infections after allogeneic hematopoietic cell transplantation: impact of T cell-replete transplantation from a haploidentical donor. Biol Blood Marrow Transplant. 2018;24:109–118.
   PubMed Web of Science ®Google Scholar
• Luznik L, Bolaños-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115:3224–3230.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, Milton DR, Poon LM, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen–matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20:1975–1981.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–2444.
   PubMed Web of Science ®Google Scholar
• Dorado N. CMV reactivation after haploidentical stem cell transplantation with post-transplant cyclophosphamide promotes NK cell maturation (abstract). Bone Marrow Transplant. 2019;53:491.
   Google Scholar
• de Padua Silva L, Patah PA, Saliba RM, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica. 2010;95:1183–1190.
   PubMed Web of Science ®Google Scholar
• Raiola A, Dominietto A, Varaldo R, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma. Bone Marrow Transplant. 2014;49:190–194.
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Roth-Guepin G, Battipaglia G, et al. Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients. Transpl Infect Dis. 2015;17:822–830.
   PubMed Web of Science ®Google Scholar
• Sedláček P, Petterson T, Robin M, et al. Incidence of adenovirus infection in hematopoietic stem cell transplantation recipients: findings from the advance study. Biol Blood Marrow Transplant. 2019;25:810–818.
   PubMedGoogle Scholar
• Horlock C, Skulte A, Mitra A, et al. Manufacture of GMP-compliant functional adenovirus-specific T-cell therapy for treatment of post-transplant infectious complications. Cytotherapy. 2016;18:1209–1218.
   PubMed Web of Science ®Google Scholar
• Sun Y-Q, Xu L-P, Liu D-H, et al. The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion. Clin Microbiol Infect. 2012;18:997–1003.
   PubMed Web of Science ®Google Scholar
• Sun Y, Meng F, Han M, et al. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in china: a multicenter prospective observational study. Biol Blood Marrow Transplant. 2015;21:1117–1126.
   PubMed Web of Science ®Google Scholar
• Oarbeascoa G, Dorado N, Kwon M. Invasive fungal infection after peripheral blood nonmanipulated haploidentical SCT with post-transplant cyclophosphamide (abstract). Bone Marrow Transplant. 2019;54:410.
   Web of Science ®Google Scholar
• Yu S, Huang F, Wang Y, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2020;34:1433–1443.
   PubMed Web of Science ®Google Scholar
• Yu S, Huang F, Fan Z, et al. Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data. J Hematol Oncol. 2020;13:18.
   PubMed Web of Science ®Google Scholar
• Ringdén O, Labopin M, Ciceri F, et al. Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings? Leukemia. 2016;30:447–455.
   PubMed Web of Science ®Google Scholar
• Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361:478–488.
   PubMed Web of Science ®Google Scholar
• Crucitti L, Crocchiolo R, Toffalori C, et al. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia. 2015;29:1143–1152.
   PubMed Web of Science ®Google Scholar
• Vago L. Clonal evolution and immune evasion in posttransplantation relapses. Hematology. 2019;2019:610–616.
   PubMedGoogle Scholar
• Dholaria B, Savani BN, Labopin M, et al. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT. Haematologica. 2020;105:47–58.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Shah MV, Saliba RM, et al. Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2018;24:1232–1236.
   PubMed Web of Science ®Google Scholar
• Solomon SR, Aubrey MT, Zhang X, et al. Selecting the best donor for haploidentical transplant: impact of HLA, killer cell immunoglobulin-like receptor genotyping, and other clinical variables. Biol Blood Marrow Transplant. 2018;24:789–798.
   PubMed Web of Science ®Google Scholar
• McCurdy SR, Zhang M-J, St. Martin A, et al. Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Adv. 2018;2:299–307.
   PubMed Web of Science ®Google Scholar
• Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010;16:482–489.
   PubMed Web of Science ®Google Scholar
• Bashey A, Zhang M-J, McCurdy SR, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell–replete haploidentical donor transplantation using post-transplant cyclophosphamide. JCO. 2017;35:3002–3009.
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Labopin M, Bacigalupo A, et al. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide: BM Versus PBSC in Haplo-SCT With PT-Cy. Cancer. 2018;124:1428–1437.
   PubMed Web of Science ®Google Scholar
• Gayoso J, Balsalobre P, Kwon M, et al. Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes. Eur J Haematol. 2018;101:332–339.
   PubMed Web of Science ®Google Scholar
• Kwon M, Bailén R, Pascual-Cascón MJ, et al. Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation. Blood Adv. 2019;3:3351–3359.
   PubMed Web of Science ®Google Scholar
• Bailén R, Kwon M, Pascual-Cascon MJ, et al. Post-transplant cyclophosphamide for Gvhd prophylaxis in matched unrelated donor transplantation compared to ATG-based prophylaxis. Blood. 2019;134:3285.
   Google Scholar
• Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116:4360–4367.
   PubMed Web of Science ®Google Scholar
• Neuenhahn M, Albrecht J, Odendahl M, et al. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. Leukemia. 2017;31:2161–2171.
   PubMed Web of Science ®Google Scholar
• Pei X-Y, Zhao X-Y, Chang Y-J, et al. Cytomegalovirus-specific T-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus. J Infect Dis. 2017;216:945–956.
   PubMed Web of Science ®Google Scholar
• Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119:2644–2656.
   PubMed Web of Science ®Google Scholar
• Prockop S, Doubrovina E, Suser S, et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Investig. 2020;130:733–747.
   PubMed Web of Science ®Google Scholar
• Withers B, Clancy L, Burgess J, et al. Establishment and operation of a third-party virus-specific T cell bank within an allogeneic stem cell transplant program. Biol Blood Marrow Transplant. 2018;24:2433–2442.
   PubMed Web of Science ®Google Scholar
• Gary R, Aigner M, Moi S, et al. Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts. J Transl Med. 2018;16:124.
   PubMed Web of Science ®Google Scholar
• Priesner C, Esser R, Tischer S, et al. Comparative analysis of clinical-scale IFN-γ-positive T-cell enrichment using partially and fully integrated platforms. Front Immunol. 2016;7:393.
   PubMed Web of Science ®Google Scholar
• Park HJ, Hong KT, Yun SO, et al. Successful treatment of refractory CMV colitis after haploidentical HSCT with post-transplant cyclophosphamide using CD45RA+ depleted donor lymphocyte infusion. Bone Marrow Transplant. 2019;55:1674–1676.
   Google Scholar
• Zhao X-Y, Pei X-Y, Chang Y-J, et al. First-line therapy with donor-derived Human Cytomegalovirus (HCMV)–specific T cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation. Clinl Infect Dis. 2019;70:1429–1437.
   Web of Science ®Google Scholar
• Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19:117–122.
   PubMed Web of Science ®Google Scholar
• Chiusolo P, Bug G, Olivieri A, et al. A modified post-transplant cyclophosphamide regimen, for unmanipulated haploidentical marrow transplantation, in acute myeloid leukemia: a multicenter study. Biol Blood Marrow Transplant. 2018;24:1243–1249.
   PubMedGoogle Scholar
• Russo A, Oliveira G, Berglund S, et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018;131:247–262.
   PubMed Web of Science ®Google Scholar
• Zhao X-Y, Yu -X-X, Xu Z-L, et al. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019;3:4312–4325.
   PubMed Web of Science ®Google Scholar
• Elmariah H, Kasamon YL, Zahurak M, et al. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non–first-degree related donors. Biol Blood Marrow Transplant. 2018;24:1099–1102.
   PubMed Web of Science ®Google Scholar
• Kasamon YL, Ambinder RF, Fuchs EJ, et al. Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. Blood Adv. 2017;1:288–292.
   PubMed Web of Science ®Google Scholar